NP Life Sciences Health Industry Group (NP Life Sciences Health Industry Group) Debt-to-EBITDA : -0.15 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is NP Life Sciences Health Industry Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NP Life Sciences Health Industry Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. NP Life Sciences Health Industry Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. NP Life Sciences Health Industry Group's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.14 Mil. NP Life Sciences Health Industry Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NP Life Sciences Health Industry Group's Debt-to-EBITDA or its related term are showing as below:

NPLS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -22 Med: -22 Max: -22
Current: -22

During the past 6 years, the highest Debt-to-EBITDA Ratio of NP Life Sciences Health Industry Group was -22.00. The lowest was -22.00. And the median was -22.00.

NPLS's Debt-to-EBITDA is ranked worse than
100% of 180 companies
in the Education industry
Industry Median: 1.69 vs NPLS: -22.00

NP Life Sciences Health Industry Group Debt-to-EBITDA Historical Data

The historical data trend for NP Life Sciences Health Industry Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NP Life Sciences Health Industry Group Debt-to-EBITDA Chart

NP Life Sciences Health Industry Group Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-22.00

NP Life Sciences Health Industry Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-0.15

Competitive Comparison of NP Life Sciences Health Industry Group's Debt-to-EBITDA

For the Education & Training Services subindustry, NP Life Sciences Health Industry Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NP Life Sciences Health Industry Group's Debt-to-EBITDA Distribution in the Education Industry

For the Education industry and Consumer Defensive sector, NP Life Sciences Health Industry Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NP Life Sciences Health Industry Group's Debt-to-EBITDA falls into.

NP Life Sciences Health Industry Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NP Life Sciences Health Industry Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0.022)	/	-0.001
	=	-22.00

NP Life Sciences Health Industry Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0.022)	/	-0.144
	=	-0.15

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

NP Life Sciences Health Industry Group (OTCPK:NPLS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NP Life Sciences Health Industry Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NP Life Sciences Health Industry Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

NP Life Sciences Health Industry Group (NP Life Sciences Health Industry Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Education » NP Life Sciences Health Industry Group Inc (OTCPK:NPLS) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

4125 Blackhawk Plaza Circle, Suite 166, Danville, CA, USA, 94506

Website

https://www.gjcc.us

NP Life Sciences Health Industry Group Inc offers international study tours, online and offline, in classical Chinese studies through classes, lectures, cultural, and artistic events. Its revenues are comprised of providing promotions and consulting services to its partner who gives international study tour services, commission to be received from partner enrollment services and mental health consulting services.

Executives

Guidong Wang	director, 10 percent owner, officer: Chairman, CEO. Pres, Treas	4125 BLACKHAWK PLAZA CIRCLE, SUITE 168, DANVILLE CA 94506
Huaying Zhu	director, officer: Secretary	4125 BLACKHAWK PLAZA CIRCLE, SUITE 168, DANVILLE CA 94506
Jonathan Ginsberg	director	4125 BLACKHAWK PLAZA CIRCLE, SUITE 166, DANVILLE CA 94506
Sanjun Kuang	director, officer: CEO, President and Treasurer	4125 BLACKHAWK PLAZA CIRCLE, SUITE 166, DANVILLE CA 94506
Meisang Hu	director, 10 percent owner	4125 BLACKHAWK PLAZA CIRCLE, SUITE 166, DANVILLE CA 94506
Huawei Li	director, officer: Secretary	4125 BLACKHAWK PLAZA CIRCLE, SUITE 166, DANVILLE CA 94506
Jianhua Wang	10 percent owner	4125 BLACKHAWK PLAZA CIRCLE, SUITE 166, DANVILLE CA 94506

NP Life Sciences Health Industry Group (NP Life Sciences Health Industry Group) Headlines

No Headlines